All News

Since biosimilars first launched, unique pricing incentives and strategies have been created to incentives adoption.

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Tandem Diabetes Care, Inc has reported 224 injuries associated with a software malfunction in a companion insulin app, leading the company to issue a recall of the technology.

Researchers analyzed the prior authorization requirements of private insurers applied to various Medicare services.

Test your knowledge of allergy and asthma clinical guidelines.

Designs of existing wearables overlook the specific needs of vulnerable populations, hindering their widespread adoption among increasingly interested communities.

Check out this list of resources to share with patients who are experiencing mental health conditions.

As demand for GLP-1 receptor agonist medications increases, researchers are hopeful these drugs can be used for more indications than those that currently exist.

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

The Psychopharmacologic Drugs Advisory Committee will meet June 4 to review a new drug application from Lykos Therapeutics.

The specialty drug market has exploded in the last few decades.

As medication experts, pharmacists can advocate to organizational decision makers around the benefits of biosimilars.

Data from 2024 are being used as a way to predict what changes may be on the way for 2025.

Mycophenolate mofetil oral suspension is the only FDA-approved ready-to-use liquid formulation.

Researchers continue to report on the rise of syphilis in the US, with recent cases exhibiting rare symptoms in the eyes, ears, and brain.

In case you missed it, this week we had news about marijuana reclassification, the Change Healthcare cyberattack, declining wages among community pharmacists, and more.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Check out important updates from the FDA for the week of April 29.

Two trials studying brexpiprazole in combination with sertraline "constitute one of the largest clinical development programs ever conducted in posttraumatic stress disorder (PTSD)."

Are you a Wookie with a mane to maintain or a scoundrel prone to nausea? You don’t have to traverse distant planets to find OTC recommendations that meet your needs—this guide has you covered.

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.

The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.

The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).

The organization has renewed its recommendation of Prescryptive Health’s artificial intelligence pricing system, stating it can help independent pharmacies stay competitive.

According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”

In a testimony to the Senate Finance Committee, Andrew Witty discussed what led to the February Change Healthcare cyberattack and the organization’s response.

Although the US Drug Enforcement Agency's (DEA) proposed reclassification of marijuana wouldn’t legalize the drug nationwide, it could shake up the current marijuana landscape.